33329-70-3

Basic information

• Product Name: CYCLOPROPANECARBOXYLIC ACID, 1-FORMYL-, ETHYL ESTER
• Synonyms: CYCLOPROPANECARBOXYLIC ACID, 1-FORMYL-, ETHYL ESTER;ethyl 1-forMylcyclopropanecarboxylate;ethyl 1-formylcyclopropane-1-carboxylate;1-Formyl-cyclopropanecarboxylic acid ethyl ester
• CAS NO: 33329-70-3
• Molecular Formula: C₇H₁₀O₃
• Molecular Weight: 142.153
• Mol File: 33329-70-3.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• CAS DataBase Reference: CYCLOPROPANECARBOXYLIC ACID, 1-FORMYL-, ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: CYCLOPROPANECARBOXYLIC ACID, 1-FORMYL-, ETHYL ESTER(33329-70-3)
• EPA Substance Registry System: CYCLOPROPANECARBOXYLIC ACID, 1-FORMYL-, ETHYL ESTER(33329-70-3)

Safety Data

• Hazardous Substances Data: 33329-70-3(Hazardous Substances Data)

Upstream product

• 1559-02-0 diethyl cyclopropane-1,1-dicarboxylate 
• 105-56-6 ethyl 2-cyanoacetate 
• 3697-68-5 ethyl 1-(hydroxymethyl)cyclopropanecarboxylate 
• 33329-69-0 1-(4,4,6-trimethyl-5,6-dihydro-4H-[1,3]oxazin-2-yl)-cyclopropanecarboxylic acid ethyl ester 
• 161692-19-9 1-(4,4,6-trimethyl-[1,3]oxazinan-2-yl)-cyclopropanecarboxylic acid ethyl ester 
• 1558-81-2 1-carbethoxy-1-cyanocyclopropane 

Downstream Products

• 1314397-71-1 1-(difluoromethyl)cyclopropane-1-carboxylic acid 
• 1620070-16-7 C₂₅H₂₃N₃O₄ 
• 1620074-79-4 C₂₇H₂₇N₃O₄ 
• 1144518-14-8 C₁₂H₂₂N₂O₂ 
• 161692-17-7 1-(1-cyano-1-ureidomethyl)-1-ethoxycarbonyl cyclopropane 

Relevant articles and documents

BENZYL-1H-PYRAZOLO[3,4-B]PYRIDINES AND USE THEREOF

The present application relates to novel benzyl-1H-pyrazolo[3,4-b]pyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.